Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | How to improve transplant outcomes in MDS?

Stephen Nimer • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine

Stephen Nimer, MD, Sylvester Comprehensive Cancer Center and University of Miami, Miami, FL, discusses how to improve the outcomes of transplants in myelodysplastic syndromes (MDS) patients. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Stephen Nimer

1:18
Update on immunotherapy in MDS
Stephen Nimer • 5 Mar 2020
1:02
Stephen Nimer: MDS highlights
Stephen Nimer • 5 Mar 2020
1:19
The promise of precision medicine in MDS
Stephen Nimer • 5 Mar 2020
1:01
Evolving role of next-generation sequencing in MDS
Stephen Nimer • 5 Mar 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals